Palmitoylethanolamide and Luteolin for Postinfectious Olfactory Disorders: How Clinically Meaningful Is Its Effect?
Randomised controlled trialHumansWith luteolin
This study tested palmitoylethanolamide together with luteolin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Randomised controlled trial
- Subjects
- 50 outpatients with lasting loss of smell after a respiratory infection, mostly COVID-19
- Dose used in the study
- Palmitoylethanolamide with luteolin, added to olfactory training. The comparison group did olfactory training alone.
- What was measured
- Smell function before and after treatment, including odour discrimination
What the authors reported
The authors reported that the supplement group improved in odour discrimination and overall smell scores, and the training-only group did not. When they counted clinically meaningful improvements, they found no significant difference between the groups. They conclude that the added benefit over training alone may be marginal.
Limits of this study
An independent group from the Dresden smell clinic, and their result is more cautious than the Italian trials of the same combination in this database. No placebo. 50 patients. The entry was checked against the abstract only.
Source
Entry checked against the abstract and citation held by Crossref, the DOI registry on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.